Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. HANSEATISCHE WERTPAPIERBOERSE HAMBURG
  5. Sangui Biotech International, Inc.
  6. News
  7. Summary
    SBH   US80105B1017

SANGUI BIOTECH INTERNATIONAL, INC.

(SBH)
SummaryChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE : Sangui BioTech International Inc.: Granulox is awarded the prestigious Prix Galien

10/21/2021 | 05:17am EST

DGAP-News: Sangui BioTech International Inc. / Key word(s): Miscellaneous Sangui BioTech International Inc.: Granulox is awarded the prestigious Prix Galien 2021-10-21 / 11:16 The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

Sangui BioTech:

- Granulox is awarded the prestigious Prix Galien

Hamburg, October 21, 2021: The wound spray Granulox developed by Sangui and licensed to Mölnlycke Health Care GmbH was awarded the Prix Galien for the best medical product of 2020 in Belgium and Luxembourg. The Prix Galien is awarded annually. The awards were created in France in 1970 by the pharmacist Roland Mehl in honor of Galen, the father of medical science and modern pharmacology. The Prix Galien honors the world's most innovative drugs and medical devices. It is considered the equivalent of the Nobel Prize in the pharmaceutical and medical industries.

"We congratulate the entire Mölnlycke team for this terrific success. The fact that the expert jury voted for Granulox, despite the nomination of medical products from such renowned manufacturers as Siemens Healthineers, BeWell Industries, Norgine and Sunrise, underscores and further validates the importance of the therapy for the healing of chronic wounds researched and developed by Prof. Dr. Dr. Wolfgang Barnikol and Dr. Harald Pötzschke. This award honors the commitment of everyone involved in this project - from basic research to successful market launch" Hubertus Schmelz, Managing Director of SanguiBio Tech GmbH, is delighted.

Link to the press release from Mölnlycke Health Care: https://www.molnlycke.com/news/molnlycke-news/ granulox-wins-prix-galien/

Link to the video of the award ceremony: https://www.artsenkrant.com/actueel/ uitreiking-galenusprijs-2020-winnaars-in-beeld/video-normal-57403.html?cookie_check=1634234307

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact: Sangui Biotech International, Inc. Thomas Striepe Fax: +49 (40)46093120 e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

-----------------------------------------------------------------------------------------------------------------------

2021-10-21 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

-----------------------------------------------------------------------------------------------------------------------

1242527 2021-10-21

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1242527&application_name=news

(END) Dow Jones Newswires

October 21, 2021 05:16 ET (09:16 GMT)

All news about SANGUI BIOTECH INTERNATIONAL, INC.
11/15SANGUI BIOTECH INTERNATIONAL INC. : - Sales of USD 18,560 in first quarter - Reduction of ..
EQ
11/12SANGUI BIOTECH INTERNATIONAL INC Management's Discussion and Analysis of Financial Con..
AQ
11/12Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended..
CI
10/21SANGUI BIOTECH INTERNATIONAL INC. : Granulox is awarded the prestigious Prix Galien
EQ
09/29SANGUI BIOTECH INTERNATIONAL INC. : - Sales of USD 65,582 in fiscal year 2021 - Reduction ..
EQ
09/28SANGUI BIOTECH INTERNATIONAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
09/28Sangui Biotech International, Inc. Reports Earnings Results for the Full Year Ended Jun..
CI
05/11SANGUI BIOTECH INTERNATIONAL INC. : - Granulox(R) - Follow up
EQ
05/10SANGUI BIOTECH INTERNATIONAL INC. : - Significant increase in sales in the first nine mont..
EQ
05/07SANGUI BIOTECH INTERNATIONAL : Management's Discussion and Analysis of Financial Condition..
AQ
More news
Financials (USD)
Sales 2021 0,07 M - -
Net income 2021 -0,20 M - -
Net Debt 2021 0,79 M - -
P/E ratio 2021 -21,6x
Yield 2021 -
Capitalization 3,36 M 3,30 M -
EV / Sales 2020 134x
EV / Sales 2021 90,6x
Nbr of Employees -
Free-Float 77,5%
Chart SANGUI BIOTECH INTERNATIONAL, INC.
Duration : Period :
Sangui Biotech International, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Thomas Striepe President, CEO, CFO & Director
Hubertus Schmelz Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SANGUI BIOTECH INTERNATIONAL, INC.0.00%3
MODERNA, INC.197.32%125 937
LONZA GROUP AG28.34%58 955
IQVIA HOLDINGS INC.44.70%49 527
SEAGEN INC.-9.64%28 937
CELLTRION, INC.-41.09%24 625